Nostrum Laboratories, Inc. is voluntarily recalling 2 (two) lots of Metformin HCl Extended Release Tablets, USP 500 mg to the consumer level. The Metformin HCl Extended Release Tablets, USP 500 mg ...
Nostrum Laboratories is recalling Metformin HCl Extended Release Tablets because of NDMA above the acceptable daily intake limit. Nostrum Laboratories (Kansas City, MO) announced on Nov. 2, 2020 that ...
Pharma Major Lupin Limited announced today that its US subsidiary, Lupin Pharmaceuticals, Inc. (LPI) has received final approval for its Metformin Hydrochloride extended release tablets (HCl ER) 500 ...
Metformin is a generic prescription medication used to help manage blood sugar levels in adults and some children with type 2 diabetes. It works by decreasing sugar production in the liver, reducing ...
Granules Pharmaceuticals, Inc., Chantilly, VA is voluntarily recalling twelve (12) lots of Metformin Hydrochloride Extended-Release Tablets USP, 750 mg, 100 and 500 count bottles within expiry to the ...
PRINCETON, N.J. & LONDON--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (NYSE: BMY), and AstraZeneca (NYSE: AZN) today announced that KOMBIGLYZE ™ XR (saxagliptin and metformin HCl extended-release), ...
Dr. Reddy’s Laboratories Ltd. on Thursday announced its launch of Saxagliptin and Metformin Hydrochloride Extended-Release Tablets in the U.S. market. It is the generic version of KOMBIGLYZE XR ...
HYDERABAD, India--(BUSINESS WIRE)--Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as "Dr. Reddy's"), today ...
Aurobindo Pharma Ltd has received final approval from the US Food & Drug Administration (US FDA) to manufacture and market Metformin Hydrochloride Extended-Release (ER) Tablets USP 500 mg and 750 mg ...
Zydus Lifesciences Ltd. (formerly known as Cadila Healthcare Ltd.), has received final approval from the United States Food and Drug Administration (USFDA) to market Empagliflozin and Metformin ...
Adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes who are not adequately controlled on metformin or sitagliptin alone or in patients already being treated with ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback